Cephalexin
- Generic Name
- Cephalexin
- Brand Names
- Keflex
- Drug Type
- Small Molecule
- Chemical Formula
- C16H17N3O4S
- CAS Number
- 15686-71-2
- Unique Ingredient Identifier
- 5SFF1W6677
- Background
Cephalexin is the first of the first generation cephalosporins. This antibiotic contains a beta lactam and a dihydrothiazide. Cephalexin is used to treat a number of susceptible bacterial infections through inhibition of cell wall synthesis. Cephalexin was approved by the FDA on 4 January 1971.
- Indication
Cephalexin is indicated for the treatment of certain infections caused by susceptible bacteria. These infections include respiratory tract infections, otitis media, skin and skin structure infections, bone infections, and genitourinary tract infections.
- Associated Conditions
- Bone Infection, Genitourinary tract infection, Otitis Media (OM), Respiratory Tract Infections (RTI), Skin and skin structure infections, Acute Prostatitis
- Associated Therapies
- -
Advanced Drug Delivery Technologies for Enhancing Bioavailability and Efficacy of Risperidone
Risperidone, a second-generation antipsychotic, treats schizophrenia, bipolar disorder, and autism-related hyperactivity. It inhibits D2 dopamine and 5-HT2A serotonin receptors, reducing psychotic symptoms. Risperidone nano/microcarriers enhance bioavailability, reduce side effects, and improve patient compliance. Formulation strategies include liposomes, nanoparticles, nanoemulsions, and niosomes, aiming to improve solubility, stability, and targeted delivery. Toxicological studies highlight neurological and immunosuppressive side effects. Clinical trials show efficacy in psychosis management, and patents focus on innovative formulations. Future research aims to optimize nano/microcarrier systems for better drug delivery.
Clindamycin and bacterial load reduction as prophylaxis for surgical site infection
A trial in Tropical North Queensland aims to reduce surgical site infections (SSI) in skin cancer surgery below the knee using oral clindamycin and preoperative chlorhexidine wash with nasal mupirocin. This double-blind, placebo-controlled study will compare three arms: bacterial load reduction, clindamycin, and standard care. The primary outcome is SSI incidence, with secondary measures including adverse reactions and antibiotic resistance patterns. The trial seeks to improve patient outcomes and promote antibiotic stewardship.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath